BiotechTube

Garadacimab

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hereditary Angioedema

Conditions

Hereditary Angioedema

Trial Timeline

Mar 19, 2025 → Jun 15, 2026

NCT ID
NCT06806657

About Garadacimab

Garadacimab is a approved stage product being developed by CSL for Hereditary Angioedema. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06806657. Target conditions include Hereditary Angioedema.

What happened to similar drugs?

1 of 20 similar drugs in Hereditary Angioedema were approved

Approved (1) Terminated (0) Active (19)
🔄KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
🔄Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
🔄KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3
🔄KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3
🔄Canakinumab + PlaceboNovartisPhase 3
🔄EmicizumabRochePhase 3
🔄NitisinoneSwedish Orphan BiovitrumPhase 3

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06806657ApprovedRecruiting

Competing Products

20 competing products in Hereditary Angioedema

See all competitors
ProductCompanyStageHype Score
KVD900KalVista PharmaceuticalsPhase 2
29
KVD824 + Placebo to KVD824KalVista PharmaceuticalsPhase 1
23
KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
38
SebetralstatKalVista PharmaceuticalsPre-clinical
20
KVD900 + Placebo to KVD900KalVista PharmaceuticalsPhase 1
23
SebetralstatKalVista PharmaceuticalsPre-clinical
24
Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
34
KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tabletKalVista PharmaceuticalsPhase 1
23
KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3
34
KVD824 + Placebo to KVD824KalVista PharmaceuticalsPhase 2
21
KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3
38
Deferasirox FCTNovartisPhase 2
27
Canakinumab + PlaceboNovartisPhase 3
40
IlarisNovartisPre-clinical
33
Standard of Care for Haemophilia ARochePre-clinical
26
EmicizumabRochePhase 3
40
TafamidisPfizerPre-clinical
26
tafamidisPfizerPre-clinical
26
NitisinoneSwedish Orphan BiovitrumPre-clinical
26
NitisinoneSwedish Orphan BiovitrumPhase 1
29